Granules India's US subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with 'No Action Indicated' (NAI) status from the US FDA. The inspection was conducted at its Manassas, Virginia packaging facility between December 1 and 3, 2025. This marks the second consecutive time the facility has cleared an FDA audit with zero observations, following a similar result in March 2023. The facility serves as a critical distribution hub for the company's US front-end OTC and prescription product operations.

Granules India has successfully allotted 51.28 lakh equity shares to institutional investors and 2.5 crore convertible warrants to the promoter group and select non-promoters. The allotment was priced at Rs 585 per share/warrant, with the company immediately raising Rs 300 crore from equity and Rs 365.6 crore as a 25% upfront warrant payment. This significant capital infusion, largely backed by the promoter group, indicates strong internal confidence and provides a substantial war chest for future growth. On a fully diluted basis, the total share capital will increase to 27.28 crore shares.

Granules India has received shareholder approval for a significant fundraise through a preferential issue of securities. The company plans to issue up to 2,50,00,000 convertible warrants and 51,28,205 equity shares to specific investors. The pricing will be subject to recomputation as per SEBI ICDR Regulations if required. Until the proceeds are fully utilized for their intended objects, the funds will be parked in low-risk instruments like debt mutual funds and government securities.

Granules India reported a strong Q3 FY26 with revenue growing 22% YoY to ₹1,388 crores, driven by robust performance in North America and Europe. EBITDA increased 34% to ₹308 crores, with margins expanding to 22.2% despite a ₹24.8 crore loss in the nascent Peptide CDMO segment. The company is making steady progress on regulatory remediation at its Gagillapur facility, following a constructive meeting with the US FDA in January 2026. Additionally, shareholders have approved a preferential issue to strengthen the balance sheet and fund future capacity expansions.

Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and scaling of the complex generics portfolio. The company maintained a healthy ROCE of 16.8% and reduced its Net Debt/EBITDA ratio to 0.91x.

Granules India reported a strong Q3FY26 with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and operational efficiencies. The company also received a credit rating upgrade from ICRA to AA and reported zero observations for its US packaging facility.

Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to INR 13,879 Mn, primarily driven by the Finished Dosages segment in North America and Europe. Profitability improved significantly as EBITDA rose 34% YoY to INR 3,081 Mn, with margins expanding to 22% from 20% in the previous year. Net profit (PAT) increased 28% YoY to INR 1,502 Mn, reflecting efficient execution and vertical integration. The company maintains a healthy balance sheet with a Net Debt to EBITDA ratio of 0.91x and a ROCE of 16.8%.

Granules India reported a 6.3% YoY increase in standalone revenue to ₹8,953.18 million for Q3 FY26, with net profit growing 23.8% to ₹1,115.82 million. The company is navigating challenges from a USFDA warning letter at its Gagillapur facility, which has led to higher remediation costs and production slowdowns. A significant fundraising plan of approximately ₹17,625 million through warrants and equity at ₹585 per share has been approved to support growth. Additionally, the company completed the acquisition of Granules Pharmaceuticals GmbH in Germany and accounted for costs related to the Senn Chemicals AG acquisition.

Granules India Limited held an Extraordinary General Meeting (EGM) on January 22, 2026, where shareholders approved two significant capital-raising resolutions. The first resolution involves the issuance of up to 2.5 crore warrants convertible into equity shares on a preferential basis, which passed with 86.69% support. The second resolution for the issuance of up to 51.28 lakh equity shares on a preferential basis received near-unanimous approval at 99.99%. These approvals provide the company with a mandate to raise capital through preferential allotments, likely aimed at funding future growth or strategic initiatives.

Granules India's US subsidiary has received tentative FDA approval for generic Amphetamine Extended-Release tablets, the generic version of DYANAVEL XR, used for ADHD treatment. Significantly, the company has secured 180-day exclusivity for this product, which addresses a market size of approximately USD 41 million. This marks the second major CNS-related tentative approval in weeks, following a December 2025 approval for a generic version of ADZENYS XR-ODT with a USD 172 million market. These developments highlight the company's successful pivot toward complex generics and differentiated products in the U.S. market.

Granules India has scheduled an Extraordinary General Meeting on January 22, 2026, to approve a total fundraise of ₹1,762.50 crores. The company plans to issue 2.5 crore convertible warrants to the promoter group at ₹585 each, totaling ₹1,462.50 crores. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors, including 360 ONE funds and the Public Sector Pension Investment Board, raising ₹300 crores. This significant capital infusion, largely backed by promoters, indicates strong internal confidence in the company's growth trajectory.

Granules India's board has approved a massive fundraise of Rs 1,762.50 crore through a mix of equity shares and convertible warrants. The company will issue 2.5 crore warrants at Rs 585 each, primarily to the promoter group, totaling Rs 1,462.50 crore. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors like 360 ONE and Public Sector Pension Investment Board for Rs 300 crore. This capital infusion is subject to shareholder approval at an EGM scheduled for January 22, 2026.